Senti Biosciences Holdings, Inc. SEC filings SNTI
Senti Biosciences Holdings, Inc. has 367 filings in SEC EDGAR's recent list, going back to Apr 2, 2021. Its latest annual report, Form ARS, was filed on Jul 21, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 27, 2026 (officer or director change, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Oct 13, 2026 | — |
| DEFM14A | Filing | Sep 24, 2026 | — |
| DEFA14A | Additional proxy material | Sep 4, 2026 | — |
| DEFA14A | Additional proxy material | Sep 2, 2026 | — |
| DEFA14A | Additional proxy material | Aug 20, 2026 | — |
| PREM14A | Filing | Jul 21, 2026 | Aug 18, 2026 |
| DEFA14A | Additional proxy material | Jul 15, 2026 | — |
| DEFA14A | Additional proxy material | Apr 30, 2025 | — |
| DEF 14A | Proxy statement | Apr 30, 2025 | Jun 25, 2025 |
| DEF 14A | Proxy statement | Jan 27, 2025 | Mar 6, 2025 |
| PRE 14A | Preliminary proxy statement | Jan 15, 2025 | Mar 6, 2025 |
| DEFA14A | Additional proxy material | May 29, 2024 | — |
| DEF 14A | Proxy statement | May 29, 2024 | Jul 10, 2024 |
| PRE 14A | Preliminary proxy statement | May 17, 2024 | May 17, 2024 |
| DEFA14A | Additional proxy material | May 1, 2023 | — |
| DEF 14A | Proxy statement | May 1, 2023 | Apr 28, 2023 |
| DEFM14A | Filing | May 13, 2022 | — |
Showing 17 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SNTI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1854270
- Former names
- Senti Biosciences, Inc. (until May 8, 2026); Senti Biosciences, Inc.\ (until Jun 28, 2022); Dynamics Special Purpose Corp. (until Jun 13, 2022)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.